Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
New Gene Therapy Approach Shows Promise for Duchenne Muscular Dystrophy July 24 ... by using a novel in vivo CRISPR genome editing ... Researchers Discover Potential Mole Reversal Therapy in ...
Stoke Therapeutics CEO Ed Kaye is stepping down, the company said. He will be replaced on an interim basis by Director Ian ...
MedPage Today on MSN11d
Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular DystrophyA young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
CRISPR technique can target single genes essential for cancer cell survival, toppling the whole structure, says nanomedicine ...
New Gene Therapy Approach Shows Promise for Duchenne Muscular Dystrophy July 24, 2024 — Researchers have made a significant breakthrough in developing a new gene therapy approach that restores ...
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback